ExploreWatchlistsPricing
  1. JP-listed companies
  2. Kyowa Kirin Co.,Ltd.
  3. Financials
  4. Cash from financing

Kyowa Kirin Co.,Ltd. (4151)

Market cap
¥1.26T
P/E ratio
16.7x
Kyowa Kirin manufactures and sells prescription pharmaceuticals through integrated operations from drug development to sales, serving healthcare markets globally.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash from financing (Million JPY)YoY (%)
Dec 31, 2025-36,853-56.49%
Dec 31, 2024-84,697+160.33%
Dec 31, 2023-32,535+12.07%
Dec 31, 2022-29,032+2.06%
Dec 31, 2021-28,446+9.40%
Dec 31, 2020-26,003-45.11%
Dec 31, 2019-47,371+187.08%
Dec 31, 2018-16,501-9.77%
Dec 31, 2017-18,287+34.48%
Dec 31, 2016-13,598-3.29%
Dec 31, 2015-14,060-62.19%
Dec 31, 2014-37,184

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat